Together with Calico’s scientists, our team identifies promising research approaches and translational science that complements and enhances our internal efforts.
Partnering with Calico
We’re not intimidated by bold ideas and risk, as we’re looking to take big leaps in the fields of aging and age-related disease. We like to collaborate with outstanding people and organizations that bring access to new biology and technology platforms. We won’t hesitate to explore unproven areas if the science and rationale are strong, and we’re not tied to specific pathways, targets or technologies.
We’re flexible in how we organize and structure partnerships. Our preference is to be deeply engaged scientifically in collaborative research programs.
Calico combines the focus and drive of a start-up with the resources and world class R&D capabilities of the leading biotechnology companies. Calico’s internal research efforts are predicated on “beyond state-of-the-art” technology and research infrastructure including advanced sequencing, computational biology and machine learning, metabolomics/proteomics, microscopy/imaging and translational biology.
Through our productive alliance with AbbVie, we have outstanding access to resources including medicinal chemistry, protein production, drug screening, and structural biology to accelerate development of therapeutic programs and discovery technologies. Partnering with Calico provides people, resources, and capabilities to advance a full range of biotechnology R&D opportunities.
See how the AbbVie-Calico Life Sciences collaboration turns the traditional partnership upside down to tackle age-related diseases. The giant tortoise can roam the Earth for over 150 years. Whales, the longest living mammals, pass two centuries without a second thought. The oldest known freshwater mussel celebrated 280 birthdays. But what about humans? What makes our cells and genes...
We’re open to many different types of partnerships with various structures, if we believe they will advance our scientific pursuits.
We focus on the following types of collaborations:
Sponsored academic research, especially projects focused on understanding the basic biology of aging and hallmarks of aging such as proteostasis and repair, stress responses, cellular energetics and senescence; other interests for sponsored research include early drug discovery and genetic studies.
Licensing and collaboration agreements for clinical-stage therapeutic programs, including, but not limited to cancer, neurodegeneration, chronic inflammation and metabolic disorders.
Novel drug discovery platforms in the areas of nucleic acid sequencing (including single cell methods and spatial transcriptomics), mass spectrometry, and imaging, to name a few.
Advanced technology and computing platforms and capabilities, including machine learning, and computer vision/perception.
We welcome proposals for partnership. If you would like to collaborate with Calico, please provide us with a brief non-confidential proposal that describes the opportunity, including scientific supporting data, to email@example.com